Back to top

Mizuho Securities Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)

In a report released on July 17, Joseph Catanzaro from Mizuho Securities maintained a Buy rating on Tango Therapeutics, with a price target of $40....

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Tango Therapeutics, Inc. (TNGX)